Ibrexafungerp:一个叙事概述
L'Emir Wassim El Ayoubi1, Fatima Allaw1, Elie Moussa2
1Division of Infectious Diseases, American University of Beirut Medical Center, Beirut, Lebanon.
Current research in microbial sciences
|June 14, 2024
概括
伊布雷克萨格尔普 (IBX) 是一种新型抗真菌药物,可以抑制真菌细胞壁的合成. 它在抗性菌株和临床试验中显示出对各种感染的有效性,包括 vulvovaginal candidiasis.
科学领域:
- 菌类学 菌类学是指菌类学.
- 药理学 药理学是指药理学的学科.
- 传染性疾病 传染性疾病
背景情况:
- 伊布雷克萨格尔普 (IBX) 是一种新的抗真菌剂,向真菌细胞壁合成.
- 它抑制β-(1,3)-D-葡萄糖 (BDG) 合成酶,提供与现有的抗真菌药物不同的机制.
- IBX对广泛的真菌病原体表现出活性,包括耐药菌株.
研究的目的:
- 评估作为一种新型抗真菌剂的ibrexafungerp (IBX) 的疗效和安全性.
- 评估IBX对各种真菌物种的活性,包括耐药菌株和临床前模型.
- 审查IBX在治疗 кандидоз和阿斯伯吉洛症方面的临床试验数据.
主要方法:
- 对IBX的作用机制,活性谱和药理动力学性质的临床前数据的审查.
- 在体研究中对入侵性候群病 (IC) 和入侵性肺阿斯伯吉洛症 (IPA) 的小鼠模型进行分析.
- 检查临床试验结果,检查 vulvovaginal candidasis (VVC),IC,以及新出现的病原体,如 *Candida auris*.
主要成果:
- IBX表现出广泛的活性,包括对抗耐醇和耐氨菌株,并具有抗生物膜特性.
- 药物动力学研究表明,具有良好的生物可用性和组织分布,药物相互作用潜力较低.
- 临床试验表明IBX在VVC治疗和预防方面不低于可纳,在IC和*C. auris*感染方面取得了有希望的结果.
结论:
- 伊布雷克萨格柏 (IBX) 是抗真菌疗法的重大进展,因为它具有独特的机制和广泛的活性.
- 它在VVC临床试验中的有效性和对侵入性真菌感染的有希望的结果证明了它在抗真菌武器库中的地位.
- 建议对IBX进行进一步的研究,特别是在复杂和耐火性真菌感染中.
关键词:
它们是Candida auris.在Ibrexafungerpp中使用侵袭性角膜炎症是一种侵袭性疾病.侵袭性肺部阿斯伯吉洛症 (Aspergillosis) 是一种侵袭性肺部阿斯伯吉洛症.Vulvovaginal 候选症的发生更多相关视频
08:04Author Spotlight: Investigating Islet Abnormalities and Function with a Pseudoislet Protocol
Published on: November 3, 2023
1.9K
05:28Monitoring On-Target Signaling Responses in Larval Zebrafish - Z-REX Unmasks Precise Mechanisms of Electrophilic Drugs and Metabolites
Published on: June 2, 2023
800
相关概念视频
01:16Drug Biotransformation: Overview
2.4K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.4K
01:17Drug Absorption: Overview
572
The process of drug absorption signifies the transition of a drug from its site of administration into the plasma. This process is influenced by various factors, including the route of administration, the anatomy of the absorption site, the mechanism of absorption, gut motility, and the drug's physicochemical properties.
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI)...
When drugs are injected intravenously, they directly enter the systemic circulation. Alternatively, orally administered drugs navigate through the gastrointestinal (GI)...
572
01:24Glucagon-like Receptor Agonists
316
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
316
01:17Drugs for Treatment of Diarrhea-Predominant IBS
157
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
157
01:21Drugs for Treatment of Constipation-Predominant IBS
155
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
155
01:28Biopharmaceutics and Pharmacokinetics: Overview
2.0K
Understanding drugs, drug products, and their performance in pharmaceutical science is pivotal. Drugs, whether simple molecules or complex compounds, are designed to interact with the body's biological systems to diagnose, treat, or prevent diseases. Drug products include various delivery systems such as tablets, capsules, injections, and inhalers. The performance of these drug products is gauged by their ability to deliver the active ingredient to the desired site of action at the...
2.0K